scholarly journals FOLLOW-UP OF PATIENTS AND PROGNOSTIC IMPACT OF TUMOUR MARKER CA 15-3 ON PATIENTS OF BREAST CANCER: A RETROSPECTIVE COHORT STUDY

2020 ◽  
Vol 8 (11) ◽  
pp. 656-660
Author(s):  
Anjali Vinocha ◽  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Cancer Patients ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Relative Survival ◽  
Rank Test ◽  
Prognostic Impact ◽  
Breast Cancer Patients

Introduction:Breast cancer is the most common cancer in women, with 5- and 10-year relative survival rates are 91% and 84%, respectively for women with invasive breast cancer. This study aimed to detect the role of serum breast cancer marker CA 15-3 for early detection of metastasis, relapse or recurrence for management of breast cancer patients. Methods: It was a retrospective cohort study with a total of 132 breast cancer patients from the year 2010 to march 2020 were taken and followed up. For these patients demographic, biochemical parameters, radiological and clico-pathological data were collected and analysed. Result: The mean age at the time of presentation and mean duration of follow-up was 47 years and 31 months respectively. There was elevation in the serum level of CA 15-3 at the time of diagnosis of metastasis, recurrence or residual disease in 41 patients. This shows that sensitivity of elevated CA 15-3 (> 30 IU/ml) level in Ca Breast patients was 84%, 75 % and 75 % with respect to metastasis, recurrence and relapse. Log Rank test Chi- square value was 7.39 which was statistically significant (p=0.007). Cox proportional hazard model was created for effect of age at presentation, CA 15-3 at the time of diagnosis and MRM on distant metastasis and was statistically significant (p=0.037). Conclusion: We recommend that for the management of breast cancer patients, Cancer antigen (CA 15-3) levels can be used as prognostic marker for early diagnosis of metastasis, recurrence or relapse.

scholarly journals Knowing Cancer Diagnosis is a Protective Factor for the Survival of Patients With Breast Cancer : A Retrospective Cohort Study

2020 ◽  
Author(s):  
Chen He ◽  
Wenxi Zhu ◽  
Yunxiang Tang ◽  
Yonghai Bai ◽  
Zheng Luo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Survival Time ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Breast Cancer Patients ◽  
Term Survival ◽  
Cox Regression Analysis

Abstract Background: The health burden of breast cancer is rising in China. The effect of informed diagnosis on long-term survival has not been fully understood. This retrospective cohort study aims at exploring the association between early informed diagnosis and survival time in breast cancer patients.Methods: 12,327 breast cancer patients were enrolled between October 2002 and December 2016. Potential factors including knowing cancer diagnosis status, gender, age, clinical-stage, surgical history, the grade of reporting hospital and diagnostic year were registered. We followed up all participants every 6 months until June 2017.Results: By June 2017, 18.04% of the participants died of breast cancer. Both the 3-year and 5-year survival rate of whom knew cancer diagnosis were longer (P<0.001). By stratified analysis, except subgroups of male patients and patients in stage III, patients knowing diagnosis showed a better prognosis in all the other subgroups (P<0.05). By Cox regression analysis, it was showed that not knowing cancer diagnosis was an independent risk factor for survival in breast cancer patients (P<0.001).Conclusions: Being aware of their cancer diagnosis plays a protective role in extending the survival time in breast cancer patients, which suggests medical staff and patients’ families disclose cancer diagnosis to patients timely.

scholarly journals A Comparison between Cure Model and Recursive Partitioning: A Retrospective Cohort Study of Iranian Female with Breast Cancer

2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
Mozhgan Safe ◽  
Javad Faradmal ◽  
Hossein Mahjub
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Cancer Patients ◽  
Simulation Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Recursive Partitioning ◽  
Breast Cancer Patients ◽  
Cure Model ◽  
Model Based

Background. Breast cancer which is the most common cause of women cancer death has an increasing incidence and mortality rates in Iran. A proper modeling would correctly detect the factors’ effect on breast cancer, which may be the basis of health care planning. Therefore, this study aimed to practically develop two recently introduced statistical models in order to compare them as the survival prediction tools for breast cancer patients.Materials and Methods. For this retrospective cohort study, the 18-year follow-up information of 539 breast cancer patients was analyzed by “Parametric Mixture Cure Model” and “Model-Based Recursive Partitioning.” Furthermore, a simulation study was carried out to compare the performance of mentioned models for different situations.Results. “Model-Based Recursive Partitioning” was able to present a better description of dataset and provided a fine separation of individuals with different risk levels. Additionally the results of simulation study confirmed the superiority of this recursive partitioning for nonlinear model structures.Conclusion. “Model-Based Recursive Partitioning” seems to be a potential instrument for processing complex mixture cure models. Therefore, applying this model is recommended for long-term survival patients.

Tamoxifen and Gallstone Formation in Postmenopausal Breast Cancer Patients: Retrospective Cohort Study

2003 ◽  
Vol 27 (4) ◽  
pp. 395-399 ◽  
Author(s):  
Mehmet L. Akin ◽  
Haldun Uluutku ◽  
Cengiz Erenoglu ◽  
Ahmet Karadag ◽  
Bahad?r M. Gulluoglu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Cancer Patients ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Postmenopausal Breast Cancer ◽  
Gallstone Formation ◽  
Breast Cancer Patients

scholarly journals Prevalence and Risk Factors of Ovarian Metastases in Breast Cancer Patients < 41 Years of Age in the Netherlands: A Nationwide Retrospective Cohort Study

PLoS ONE ◽  
2017 ◽  
Vol 12 (1) ◽  
pp. e0168277 ◽  
Author(s):  
Inge T. A. Peters ◽  
Erik W. van Zwet ◽  
Vincent T. H. B. M. Smit ◽  
Gerrit Jan Liefers ◽  
Peter J. K. Kuppen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Cohort Study ◽  
The Netherlands ◽  
Cancer Patients ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Breast Cancer Patients ◽  
Ovarian Metastases

scholarly journals Primary Care Continuity and Wait Times to Receiving Breast Cancer Chemotherapy: A Population-Based Retrospective Cohort Study Using CanIMPACT Data

2021 ◽  
Vol 28 (6) ◽  
pp. 4786-4804
Author(s):  
Rachel Lin Walsh ◽  
Aisha Lofters ◽  
Rahim Moineddin ◽  
Monika Krzyzanowska ◽  
Eva Grunfeld
Keyword(s):  
Breast Cancer ◽  
Primary Care ◽  
Cohort Study ◽  
Cancer Patients ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Population Based ◽  
Wait Times ◽  
Breast Cancer Patients ◽  
Breast Cancer Chemotherapy

(1) Background: Wait times to chemotherapy are associated with morbidity and mortality in breast cancer patients; however, it is unclear how primary care physician (PCP) continuity impacts these wait times, or whether this association is different in immigrants, who experience cancer care inequities. We assessed the association between PCP continuity and the contact-to-chemotherapy interval (wait time from when a patient first presents to healthcare to the first day of receiving breast cancer chemotherapy), with a specific look at the immigrant population. (2) Methods: Population-based, retrospective cohort study of women who were diagnosed with stage I–III breast cancer in Ontario who received surgery and adjuvant chemotherapy. We used quantile regression at the median and 90th percentile to quantify the effect of PCP continuity on the contact-to-chemotherapy interval, performing a separate analysis on the immigrant population. (3) Results: Among 12,781 breast cancer patients, including 1706 immigrants, the median contact-to-chemotherapy interval (126 days) was 3.21 days shorter (95% confidence interval (CI) 0.47–5.96) in symptom-detected patients with low PCP continuity, 10.68 days shorter (95% CI 5.36–16.00) in symptom-detected patients with no baseline PCP visits and 17.43 days longer (95% CI 0.90–34.76) in screen-detected immigrants with low PCP continuity compared to the same groups with high PCP continuity. (4) Conclusions: Higher PCP continuity was not associated with a change in the contact-to-chemotherapy interval for most of our study population, but was associated with a marginally longer interval in our symptom-detected population and a shorter contact-to-chemotherapy interval in screen-detected immigrants. This highlights the importance of PCP continuity among immigrants with positive screening results. Additionally, having no PCP visits at baseline was associated with a shorter contact-to-chemotherapy interval in symptom-detected patients.

Sign in / Sign up

Export Citation Format

Share Document